{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:17:38Z","timestamp":1793636258098,"version":"4.5.1"},"reference-count":92,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>\n                    Alpha-1 antitrypsin (AAT) is a protease inhibitor belonging to the serpin family. A number of identified mutations in the\n                    <jats:italic toggle=\"yes\">SERPINA1<\/jats:italic>\n                    gene encoding this protein result in alpha-1 antitrypsin deficiency (AATD). A decrease in AAT serum concentration or reduced biological activity causes considerable risk of chronic respiratory and liver disorders. As a monogenic disease, AATD appears to be an attractive target for gene therapy, particularly for patients with pulmonary dysfunction, where augmentation of functional AAT levels in plasma might slow down respiratory disease development. The short AAT coding sequence and its activity in the extracellular matrix would enable an increase in systemic serum AAT production by cellular secretion.\n                    <jats:italic toggle=\"yes\">In vitro<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                    experimental AAT gene transfer with gamma-retroviral, lentiviral, adenoviral, and adeno-associated viral (AAV) vectors has resulted in enhanced AAT serum levels and a promising safety profile. Human clinical trials using intramuscular viral transfer with AAV1 and AAV2 vectors of the AAT gene demonstrated its safety, but did not achieve a protective level of AAT &gt;11\u2009\u03bc\n                    <jats:italic toggle=\"yes\">M<\/jats:italic>\n                    in serum. This review provides an in-depth critical analysis of current progress in AATD gene therapy based on viral gene transfer. The factors affecting transgene expression levels, such as site of administration, dose and type of vector, and activity of the immune system, are discussed further as crucial variables for optimizing the clinical effectiveness of gene therapy in AATD subjects.\n                  <\/jats:p>","DOI":"10.1089\/hum.2015.044","type":"journal-article","created":{"date-parts":[[2015,9,28]],"date-time":"2015-09-28T10:22:34Z","timestamp":1443435754000},"page":"709-718","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy"],"prefix":"10.1177","volume":"26","author":[{"given":"Joanna","family":"Wozniak","sequence":"first","affiliation":[{"name":"Nicolaus Copernicus University in Torun","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wandtke","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus University in Torun","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kopinski","sequence":"additional","affiliation":[{"name":"Nicolaus Copernicus University in Torun","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Chorostowska-Wynimko","sequence":"additional","affiliation":[{"name":"National Institute of Tuberculosis and Lung Diseases","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"391","article-title":"Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis","volume":"5","author":"Dickens JA","year":"2011","unstructured":"Dickens JA, , Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Dev Ther, 2011; 5:391\u2013405.","journal-title":"Drug Des Dev Ther"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr156"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.13.8250"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)80695-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1982.tb02701.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.6.8970377"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107475"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2013.771956"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2013.764978"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.199.1.8633137"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.1.9508014"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027308"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430340460732490"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.17.1177"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904514106"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.053"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1976"},{"key":"e_1_3_2_19_2","first-page":"2409","volume-title":"The Metabolic Basis of Inherited Disease","author":"Cox DW","year":"1989","unstructured":"Cox DW. Alpha-1-antitrypsin deficiency. In: The Metabolic Basis of Inherited Disease. Scriver CR, , Beaudet AL, Sly WS, Valle D eds. (McGraw-Hill, New York). 1989; pp. 2409\u20132437."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-9525(89)90200-X"},{"key":"e_1_3_2_21_2","first-page":"45","article-title":"Genetic variants of alpha-1 antitrypsin: Classification and clinical implications","volume":"81","author":"Pop\u0142awska B","year":"2013","unstructured":"Pop\u0142awska B, , Janciauskiene S, , Chorostowska-Wynimko J. Genetic variants of alpha-1 antitrypsin: Classification and clinical implications. Pneumonol Alergol Pol, 2013; 81:45\u201354.","journal-title":"Pneumonol Alergol Pol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00062305"},{"key":"e_1_3_2_23_2","first-page":"253","article-title":"Molecular diagnostics of alpha-1-antitrypsin deficiency in clinical practice","volume":"76","author":"Struniawski R","year":"2008","unstructured":"Struniawski R, , Szpechci\u0144ski A, , Chorostowska-Wynimko J. Molecular diagnostics of alpha-1-antitrypsin deficiency in clinical practice. Pneumonol Alergol Pol, 2008; 76:253\u2013264.","journal-title":"Pneumonol Alergol Pol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920310790848368"},{"key":"e_1_3_2_25_2","first-page":"348","article-title":"Zasady post\u0119powania diagnostycznego i opieki nad chorymi z wrodzonym niedoborem alfa-1 antytrypsyny","volume":"78","author":"Chorostowska-Wynimko J","year":"2010","unstructured":"Chorostowska-Wynimko J, , Ni\u017cankowska-Mogilnicka E. Zasady post\u0119powania diagnostycznego i opieki nad chorymi z wrodzonym niedoborem alfa-1 antytrypsyny. Pneumonol Alergol Pol, 2010; 78:348\u2013355.","journal-title":"Pneumonol Alergol Pol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.18.1.43"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.95.1.196"},{"key":"e_1_3_2_28_2","first-page":"359","article-title":"Alpha-1-antitripsin: Further genetic heterogeneity revealed by isoelectric focusing","volume":"30","author":"Kueppers F","year":"1978","unstructured":"Kueppers F, , Christopherson MJ. Alpha-1-antitripsin: Further genetic heterogeneity revealed by isoelectric focusing. Am J Hum Genet, 1978; 30:359\u2013365.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_2_29_2","first-page":"130","article-title":"Alpha-1-antitrypsin: Molecular abnormality of S variant","volume":"1","author":"Owen MC","year":"1976","unstructured":"Owen MC, , Carrell RW. Alpha-1-antitrypsin: Molecular abnormality of S variant. BMJ, 1976; 1:130\u2013131.","journal-title":"BMJ"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.73.4.1324"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603203141207"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.02.002"},{"key":"e_1_3_2_33_2","first-page":"345","article-title":"Zastosowania rekombinowanej alfa-1 antytrypsyny w terapii medycznej","volume":"174","author":"Kabzi\u0144ski J","year":"2010","unstructured":"Kabzi\u0144ski J, , K\u0119dziora J, , Majsterek I. Zastosowania rekombinowanej alfa-1 antytrypsyny w terapii medycznej. Pol Merk Lek, 2010; 174:345\u2013350.","journal-title":"Pol Merk Lek"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66781-5"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.01.016"},{"key":"e_1_3_2_36_2","first-page":"1113","article-title":"Identification and DNA sequence analysis of 15 new a1-antitrypsin variants, including two PI*QO alleles and one deficient PI*M allele","volume":"55","author":"Faber JP","year":"1994","unstructured":"Faber JP, , Poller W, , Weidinger S, et al. Identification and DNA sequence analysis of 15 new a1-antitrypsin variants, including two PI*QO alleles and one deficient PI*M allele. Am J Hum Genet, 1994; 55:1113\u20131121.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.0851"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.102798"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114578"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-384-4_9"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.006502"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-869536"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.100.3.703"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/1753465812457113"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.168.7.818"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/140.5.1494"},{"key":"e_1_3_2_47_2","first-page":"193","article-title":"Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency","volume":"3","author":"Petrache I","year":"2009","unstructured":"Petrache I, , Hajjar J, , Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics, 2009; 3:193\u2013204.","journal-title":"Biologics"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60860-1"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-136"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159408"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.3.765"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S51474"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67968"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2013.765839"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01800861"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.4.1050"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6093246"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.1.89"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.14.6482"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2017680"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840210331"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.11.6"},{"key":"e_1_3_2_64_2","first-page":"1089","volume-title":"Fundamental Virology","author":"Muzyczka N","year":"2001","unstructured":"Muzyczka N, , Berns KI. Parvoviridae: The viruses and their replication. In: Fundamental Virology. Knipe DM, , Howley PM, eds. (Lippincott Williams and Wilkins, Philadelphia). 2001; vol 2, pp. 1089\u20131121."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840400422"},{"key":"e_1_3_2_66_2","first-page":"119","article-title":"Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications","volume":"99","author":"Grieger JC","year":"2005","unstructured":"Grieger JC, , Samulski RJ. Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications. Adv Biochem Eng Biotechnol, 2005; 99:119\u2013145.","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302121"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601433103"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300994"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.10.8549-8558.1999"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.24.14384"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301422"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.06.940"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.08.022"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.3_suppl.98S"},{"key":"e_1_3_2_76_2","first-page":"440","article-title":"Intrapleural \u201coutside-in\u201d gene therapy: Therapeutics for organs of the chest via gene transfer to the pleura","volume":"7","author":"Heguy A","year":"2005","unstructured":"Heguy A, , Crystal RG. Intrapleural \u201coutside-in\u201d gene therapy: Therapeutics for organs of the chest via gene transfer to the pleura. Curr Opin Mol Ther, 2005; 7:440\u2013453.","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.09.003"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2013.168"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.51"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.182412299"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3300793"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700629"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1109522108"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80163-9"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.07.058"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04791"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801775105"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.116"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.07.051"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2007-0133OC"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2010.03.007"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5417.1168"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.118"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2015.044","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2015.044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2015.044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:11Z","timestamp":1777449371000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2015.044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1089\/hum.2015.044"],"URL":"https:\/\/doi.org\/10.1089\/hum.2015.044","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}